A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study Summary

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.

Conditions

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Interventions / Drugs

azenosertib

View on ClinicalTrials.gov ↗

Sponsor

ZNTL

Zentalis Pharmaceuticals

Oncology

D36/100

Study Details

Enrollment170 participants

Primary Completion—

Lead SponsorK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Data Retrieved2026-04-11 04:32:15.024559+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.